Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

About this update from Allarity Therapeutics, Inc.

[{"type":"image","alt":"Allarity Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allarity Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZWz91jG0GlKDMeDFLyVrBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mw--/https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e","width":300,"height":138},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ZWz91jG0GlKDMeDFLyVrBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mw--/https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e","width":300,"height":138}},"lazy":false},{"type":"text","content":"","length":48,"tagName":"p"},{"type":"text","content":"TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that CEO Thomas Jensen has been invited to participate as a speaker at Precision Medicine Forum Europe 2026, taking place May 11–12, 2026, in Stockholm, Sweden.Presentation Details:","length":455,"tagName":"p"},{"type":"text","content":"Event: Precision Medicine Forum Europe 2026Presentation Title: Dual Inhibition of PARP and WNT: A Novel Drug-Biomarker Combination in Clinical TrialsTrack: OncologyDate: Monday, May 11, 2026Time: 10:20–10:40 CEST","length":216,"tagName":"p"},{"type":"text","content":"Mr. Jensen will discuss stenoparib’s dual mechanism of action and Allarity’s predictive biomarker, the Stenoparib DRP®, based on a 414-mRNA gene expression signature, which is designed to identify patients who may be more likely to benefit from stenoparib, as well as the Company’s ongoing Phase 2 trials.","length":305,"tagName":"p"},{"type":"text","content":"Mr. Jensen will be available for individual meetings during the conference to discuss Allarity’s clinical development strategy and potential business development opportunities.","length":176,"tagName":"p"},{"type":"text","content":"About Stenoparib/2X-121Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant atten...

More updates from Allarity Therapeutics, Inc.